Hepatitis E vaccine development: a 14 year odyssey.

@article{Wu2012HepatitisEV,
  title={Hepatitis E vaccine development: a 14 year odyssey.},
  author={Ting Wu and Shao-wei Li and Jun Yu Zhang and Mun-hon Ng and Ningshao Xia and Qinjian Zhao},
  journal={Human vaccines & immunotherapeutics},
  year={2012},
  volume={8 6},
  pages={823-7}
}
The first prophylactic vaccine, Hecolin®, against hepatitis E virus (HEV) infection and the HEV associated disease was approved by China's State Food and Drug Administration (SFDA) in December 2011. Key milestones during the 14-year HEV vaccine development are summarized in this commentary.  After years of innovative research the recombinant virus-like particle (VLP) based antigen with virion-like epitopes was successfully produced in E. coli production platform on a commercial scale. Safety… CONTINUE READING